The Cholecystokinin Receptor Antagonist L-364,718 Reduces Taurocholate-induced Pancreatitis in Rats

Overview

Journal Int J Pancreatol

Specialty Gastroenterology

Date 1996 Dec 1

PMID 9013282

Citations 3

Authors

K H Kim

M G Lee

D G Kim

Affiliations

Soon will be listed here.

Abstract

Conclusion: Our results suggest that the cholecystokinin (CCK) receptor antagonist L-364,718 has a protective effect on taurocholate-induced pancreatitis, and thus, it is inferred that CCK may have a significant pathophysiological role in the early phase of pancreatitis.

Background: Conflicting results have been obtained from studies designed to determine the role of CCK in the initial stages of pancreatitis.

Methods: We evaluated the protective effect of the CCK receptor antagonist L-364,718 (devazepide) and of the trypsin inhibitor camostat, on taurocholate-induced pancreatitis in rats. L-364,718 (1 mg/kg) or camostat (200 mg/kg) was administered intragastrically 30 min before the induction of pancreatitis.

Results: Infusion of sodium taurocholate (50 mg/kg) into the pancreaticobiliary duct caused severe pancreatitis with marked hyperamylasemia and reduction of tissue enzyme content at 12 h postinfusion. Pretreatment with L-364,718, but not with camostat, caused significant improvement in signs of experimental pancreatitis based on tissue enzyme content and morphology. Compared with untreated pancreatitis, there was relatively well-preserved lobular architecture, less edema, less infiltration of inflammatory cells, and more zymogen granules after L-364,718 pretreatment. Moreover, the reduction of enzyme content owing to pancreatitis was ameliorated by L-364,718 pretreatment.

Citing Articles

Intraductal infusion of taurocholate followed by distal common bile duct ligation leads to a severe necrotic model of pancreatitis in mice.

Le T, Eisses J, Lemon K, Ozolek J, Pociask D, Orabi A Pancreas. 2014; 44(3):493-9.

PMID: 25469547 PMC: 4357535. DOI: 10.1097/MPA.0000000000000285.

The proteinase-activated receptor 2 is involved in nociception.

Hoogerwerf W, Zou L, Shenoy M, Sun D, Micci M, Xiao S J Neurosci. 2001; 21(22):9036-42.

PMID: 11698614 PMC: 6762290.

Acute taurodeoxycholate-induced pancreatitis in the rat is associated with hyperCCKemia.

Ohlsson B, Axelson J, Stenram U, Rehfeld J, Ihse I Int J Pancreatol. 2000; 27(3):195-201.

PMID: 10952401 DOI: 10.1385/IJGC:27:3:195.

References

Bruzzone R . The molecular basis of enzyme secretion. Gastroenterology. 1990; 99(4):1157-76. DOI: 10.1016/0016-5085(90)90640-m. View

Niederau C, Liddle R, Ferrell L, Grendell J . Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J Clin Invest. 1986; 78(4):1056-63. PMC: 423760. DOI: 10.1172/JCI112661. View

Makovec F, Bani M, Cereda R, Chiste R, Revel L, Rovati L . Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice. Peptides. 1986; 7(6):1159-64. DOI: 10.1016/0196-9781(86)90147-6. View

Leonhardt U, Seidensticker F, Fussek M, Stockmann F, Creutzfeldt W . Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis. Int J Pancreatol. 1991; 10(1):73-80. DOI: 10.1007/BF02924255. View

Corfield A, Cooper M, Williamson R . Acute pancreatitis: a lethal disease of increasing incidence. Gut. 1985; 26(7):724-9. PMC: 1432998. DOI: 10.1136/gut.26.7.724. View

Yu D, Huang S, Wank S, Mantey S, Gardner J, Jensen R . Pancreatic receptors for cholecystokinin: evidence for three receptor classes. Am J Physiol. 1990; 258(1 Pt 1):G86-95. DOI: 10.1152/ajpgi.1990.258.1.G86. View

Chang R, Lotti V, Monaghan R, Birnbaum J, Stapley E, Goetz M . A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science. 1985; 230(4722):177-9. DOI: 10.1126/science.2994227. View

Klar E . [Etiology and pathogenesis of acute pancreatitis]. Helv Chir Acta. 1992; 59(1):7-16. View

Otsuki M, Tani S, Okabayashi Y, Fuji M, Nakamura T, Fujisawa T . Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. Dig Dis Sci. 1990; 35(2):242-50. DOI: 10.1007/BF01536770. View

10.

Tarpila E, Larsson L, Lilja I, Ihse I . Proglumide treatment in bile-induced acute experimental pancreatitis. Int J Pancreatol. 1988; 3(2-3):195-202. DOI: 10.1007/BF02798931. View

11.

Toriumi Y, Samuel I, Wilcockson D, Turkelson C, Solomon T, Joehl R . Octreotide and cholecystokinin antagonist reduce edema in obstruction-induced acute pancreatitis. J Lab Clin Med. 1993; 122(4):450-4. View

12.

Ko T, Bertram M, Prinz R, Castelli M, Djuricin G, Jacobs H . Effect of somatostatin analogue and cholecystokinin receptor antagonist on bile-induced acute canine pancreatitis. Am Surg. 1992; 58(4):213-9. View

13.

Lotti V, Pendleton R, Gould R, Hanson H, Chang R, Clineschmidt B . In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther. 1987; 241(1):103-9. View

14.

Leonhardt U, Seidensticker F, Stockmann F, Creutzfeldt W . Effect of camostate administration for two weeks on experimental pancreatitis in mice and rats. Pancreas. 1993; 8(1):98-102. DOI: 10.1097/00006676-199301000-00017. View

15.

Sjovall S, Ahren B, Stenram U . Effects of the specific cholecystokinin antagonist L 364,718 in experimental acute pancreatitis in the rat. Eur Surg Res. 1988; 20(5-6):325-9. DOI: 10.1159/000128781. View

16.

Garcia-Montero A, Manso M, Rodriguez A, de Dios I . Therapeutic and protective effect of subcutaneous injections of L-364,718 on caerulein-induced acute pancreatitis. Pancreas. 1994; 9(3):309-15. DOI: 10.1097/00006676-199405000-00005. View

17.

Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S . Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977; 484(2):417-22. DOI: 10.1016/0005-2744(77)90097-3. View

18.

MURAMATU M, Fujii S . Inhibitory effects of -guanidino acid esters on trypsin, plasmin, plasma kallikrein and thrombin. Biochim Biophys Acta. 1972; 268(1):221-4. DOI: 10.1016/0005-2744(72)90218-5. View

19.

Agarwal N, Pitchumoni C . Assessment of severity in acute pancreatitis. Am J Gastroenterol. 1991; 86(10):1385-91. View

20.

HUMMEL B . A modified spectrophotometric determination of chymotrypsin, trypsin, and thrombin. Can J Biochem Physiol. 1959; 37:1393-9. View